In this context, PI3Kδ inhibitors represent a promising therapeutic treatment for AML without producing undesirable side effects that are conversely expected for other pan-PI3K inhibitors (Di Nicolantonio et al., 2010). The gene discussed is PIK3CD; the disease is acute myeloid leukemia.